Business
Kymera Therapeutics Appoints Healthcare Industry Leader John Maraganore, Ph.D., to Board of Directors
WATERTOWN, Mass., Jan. 18, 2022 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing targeted
About this update from Kymera Therapeutics, Inc.
[{"type":"text","content":"WATERTOWN, Mass., Jan. 18, 2022 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing targeted protein degradation to deliver novel small molecule protein degrader medicines, today announced the appointment of John Maraganore, Ph.D. to its Board of Directors. Dr. Maraganore joins Kymera’s Board after having led Alnylam Pharmaceuticals as founding CEO and Director and transformed the field of RNA therapeutics for the last nearly 20 years. “John has been a true pioneer and an inspiration for the whole biotech industry. As founding CEO of Alnylam, he has built one of the most successful biotech companies, evolving RNA therapeutics into a commercial stage therapeutic reality for patients around the globe.” said Nello Mainolfi, PhD, Co-Founder, President and Chief Executive Officer of Kymera Therapeutics. “Given our ambitions at Kymera to take a similar path and build a fully integrated global biopharma company based on targeted protein degradation, it is especially fitting and exceptionally exciting to welcome John to our Board of Directors and work with him directly to accomplish our goals and vision.” “Targeted protein degradation is a very exciting field with real transformative potential. Kymera’s differentiated pipeline and deep and unique platform investments across the spectrum of degrader approaches has clearly positioned the company as a true pioneer in the space,” said Dr Maraganore. “Kymera has already demonstrated first in class, clear and profound proof-of-mechanism and proof-of-biology with KT-474, and this year is advancing 3 clinical programs in patients across immune-inflammatory and oncology indications. Importantly, the team is advancing a new generation of additional programs, leveraging the company’s unique platform capabilities, making now an exciting time to join Kymera’s Board and contribute to our path to becoming a disease-agnostic, global degrader medicine company.” Dr. John Maraganore served as the founding CEO and a Director of Alnylam from 2002 to 2021, where he built and led the company from early platform research on RNA interference through global approval and commercialization of the first four RNAi therapeutic medicines, ONPATTRO®, GIVLAARI®, OXLUMO®, and Leqvio®. At Alnylam, he also led the company’s value creation strategy, building $25...